Miguel Martínez-Cava2025-12-22T22:02:19+01:00mAbxience and Amneal Announce FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA®Miguel Martínez-Cava2025-12-22T22:02:19+01:00December 22, 2025|
Miguel Martínez-Cava2025-12-17T10:19:49+01:00mAbxience and HP drive the use of artificial intelligence in biomanufacturing and biosimilar developmentMiguel Martínez-Cava2025-12-17T10:19:49+01:00December 4, 2025|
adriana.polo2025-11-12T12:02:38+01:00What does a company have in common with a cell?adriana.polo2025-11-12T12:02:38+01:00November 12, 2025|